Top 25 Antibiotic Drugs Manufacturers 2018

世界の抗生物質メーカー上位25社

◆タイトル:Top 25 Antibiotic Drugs Manufacturers 2018
◆商品コード:VGN808069
◆調査・発行会社:visiongain
◆発行日:2018年6月
◆ページ数:250
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥388,656見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥431,856見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥719,856見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の抗生物質メーカー上位25社"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、市場環境分析、主要企業分析、結論などの情報をお届けいたします。

Visiongain forecasts the antibiotic drugs market to increase to $ 43,841.7m in 2022. The market is estimated to grow at a CAGR of 3.4% between 2022 and 2028. In 2017, Pfizer held the largest market share of the antibiotic drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 181 tables and 111 figures– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the top 25 antibiotic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Antibiotic Drugs Market Forecast from 2018-2028, further segmented by type:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Others

Top 25 Antibiotic Drugs Manufacturers 2018

• This report provides analysis of the leading antibiotic drugs manufacturers in the US, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
• Pfizer: Sulperazon, Unasyn, Zithromax, Dalacin, Merrem/Meropen, Zyvox, Tygacil, Others
• Merck & Co.: Cubicin, Invanz, Avelox, Primaxin, Others
• Johnson & Johnson: Zeftera, Sirturo, Others
• Cubist Pharmaceuticals: Cubicin, Sivextro Oral
• Abbott Laboratories: Baxin, Others
• Eli Lilly & Co.: Vancocin, Ceclor
• Melinta Therapeutics, Inc: Orbactiv, Others

• This report provides analysis of the leading antibiotic drugs manufacturers in Europe, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
• Novartis: Vigamox, Ciprodex, TOBI Podhaler, Cubicin
• GlaxoSmithKline: Ceftin/Zinnat, Augmentin IR, Amoxil, Others
• Bayer: Avelox, Cipro/Cirpobay
• Allergan: Zinforo/Teflaro, Dalbavancin, Others
• Roche: Rocephin
• Sanofi: Targocid, Others
• STADA Arzneimittel: Amoxicillin, Diclofenac Sodium

• This report provides analysis of the leading antibiotic drugs manufacturers in Japan, including forecasts from 2018-2028 of the company’s antibiotic drugs revenues, where possible:
• Shionogi & Co., Ltd.: Flomox/Flumarin, Others
• Taisho Pharmaceutical Holdings: Geninax, Biaxin/Clarith, Zosyn/Tazocin
• Daiichi Sankyo: Cravit, Levaquin, Others
• Meiji Holdings Company, Ltd.: Meiact/Spectracef, Others
• Astellas Pharma: Dificid, Others

• This report provides analysis of the leading antibiotic drugs manufacturers in other countries, including forecasts from 2018-2028 of the company’s antibiotic drugs revenue, where possible:
• Sun Pharmaceutical Industries: Ciprofloxacin Hydrochloride, Others
• Cipla: Amoxicillin, Others
• Lupin: Cefixime, Cephalexin, Others
• Shanghai Pharmaceuticals Holding: Cefotaxime Sodium, Cefotiam Hydrochloride, Ceftriaxone Sodium
• Dr. Reddy’s Laboratories: Cefotaxime Sodium, Cefotiam Hydrochloride, Ceftriaxone Sodium
• TaiGen Biotechnology: Taigexyn

Visiongain’s study is intended for anyone requiring commercial analyses for the top 25 antibiotic drugs manufacturers. You find data, trends and predictions.

Buy our report today Top 25 Antibiotic Drugs Manufacturers 2018: US, Europe, Japan, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Others.

【レポートの目次】

1. Report Overview

1.1 Global Antibiotics Drugs Manufacturer Market Overview

1.2 Overview of Findings

1.3 Structure of the Report

1.4 Global Antibiotics Drugs Manufacturer Market Segmentation

1.5 Why You Should Read This Report

1.6 Key Questions Answered by This Analytical Report

1.7 Who is This Report For?

1.8 Methodology

1.9 Associated Visiongain Report

1.10 About Visiongain

2. Introduction to Antibiotics Drugs Manufacturer

2.1 An Introduction to Antibiotics Drugs Manufacturer

2.1.1. Cephalosporins

2.1.2. Penicillins

2.1.3. Quinolones/Fluoroquinolones

2.1.4. Macrolides

2.1.5. Carbapenems

2.2. Antibiotics Drugs Manufacturer Market: Drivers, Restrains and Opportunities

2.2.1. Drivers

2.2.1.1. Need of new broad-spectrum agents

2.2.1.2. Increase in Government Funding

2.2.1.3. Infection control in health care settings

2.2.1.4. Rapidly growing antibacterial resistance

2.2.2. Restrains

2.2.2.1. Inappropriate prescription and patient compliance

2.2.2.2. Lack of return on investment

2.2.3. Opportunities

2.2.3.1. Public-Private Funding

3. Antibiotics Drugs: World Market 2018-2028

3.1 Global Antibiotics Drugs Market Forecast, 2018-2028

3.2 Global Antibiotics Drugs Market, by Automation Type: Sales Forecast 2018-2028

3.3 Leading Antibiotics Drugs Manufacturer

3.4 Leading Companies in the Antibiotics Drugs Market

3.5 Antibiotics Drugs Market Segments: Sales Forecasts 2018-2028

3.5.1 Cephalosporins Drugs Market: Sales Forecast 2018-2028

3.5.2 Penicillins Drugs Market: Sales Forecast 2018-2028

3.5.3 Fluoroquinolones Drugs Market: Sales Forecast 2018-2028

3.5.4 Macrolides Drugs Market: Sales Forecast 2018-2028

3.5.5 Carbapenems Drugs Market: Sales Forecast 2018-2028

3.5.6 Others Drugs Market: Sales Forecast 2018-2028

4. Leading US Antibiotics Drugs Manufacturers 2018-2028

4.1 Pfizer, Inc.: Overview

4.1.1 Pfizer: Antibiotics Drugs Portfolio

4.1.2 Pfizer Antibiotics Drug Sales Forecast 2018-2028

4.1.2.1 Sulperazon

4.1.2.2 Sulperazon: Sales Forecast 2018-2028

4.1.2.3 Unasyn

4.1.2.4 Unasyn: Sales Forecast 2018-2028

4.1.2.5 Zithromax

4.1.2.6 Zithromax: Sales Forecast 2018-2028

4.1.2.7 Dalacin

4.1.2.8 Dalacin: Sales Forecast 2018-2028

4.1.2.9 Merrem/Meropen

4.1.2.10 Merrem/Meropen: Sales Forecast 2018-2028

4.1.2.11 Zyvox

4.1.2.12 Zyvox: Sales Forecast 2018-2028

4.1.2.13 Tygacil

4.1.2.14 Tygacil: Sales Forecast 2018-2028

4.1.2.15 Others

4.1.2.16 Others: Sales Forecast 2018-2028

4.1.3 Pfizer: SWOT Analysis

4.2 Merck & Co.: Overview

4.2.1 Merck & Co.: Antibiotics Drugs Portfolio

4.2.2 Merck & Co. Antibiotics Drug Sales Forecast 2018-2028

4.2.2.1 Cubicin

4.2.2.2 Cubicin: Sales Forecast 2018-2028

4.2.2.3 Invanz

4.2.2.4 Invanz: Sales Forecast 2018-2028

4.2.2.5 Avelox

4.2.2.6 Avelox: Sales Forecast 2018-2028

4.2.2.7 Primaxin

4.2.2.8 Primaxin: Sales Forecast 2018-2028

4.2.2.9 Others

4.2.2.10 Others: Sales Forecast 2018-2028

4.2.3. Merck & Co.: SWOT Analysis

4.3 Johnson & Johnson: Overview

4.3.1 Johnson & Johnson: Antibiotics Drugs Portfolio

4.3.2 Johnson & Johnson Antibiotics Drug Sales Forecast 2018-2028

4.3.2.1 Zeftera

4.3.2.2 Zeftera: Sales Forecast 2018-2028

4.3.2.3 Sirturo

4.3.2.4 Sirturo: Sales Forecast 2018-2028

4.3.2.5 Others

4.3.2.6 Others: Sales Forecast 2018-2028

4.3.3. Johnson & Johnson: SWOT Analysis

4.4 Cubist Pharmaceuticals: Overview

4.4.1 Cubist Pharmaceuticals: Antibiotics Drugs Portfolio

4.4.2 Cubist Pharmaceuticals Antibiotics Drug Sales Forecast 2018-2028

4.4.2.1 Cubicin

4.4.2.2 Cubicin: Sales Forecast 2018-2028

4.4.2.3 Sivextro Oral (Tedizolid)

4.4.2.4 Sivextro Oral: Sales Forecast 2018-2028

4.4.2.5 Others

4.4.2.6 Others: Sales Forecast 2018-2028

4.4.3. Cubist Pharmaceuticals.: SWOT Analysis

4.5 Abbott Laboratories: Overview

4.5.1. Abbott Laboratories: Antibiotics Drugs Portfolio

4.5.2 Abbott Laboratories Antibiotics Drug Sales Forecast 2018-2028

4.5.2.1 Baxin

4.5.2.2 Baxin: Sales Forecast 2018-2028

4.5.2.3 Others

4.5.2.4 Others: Sales Forecast 2018-2028

4.5.3. Abbott Laboratories.: SWOT Analysis

4.6 Eli Lilly & Co.: Overview

4.6.1. Eli Lilly & Co.: Antibiotics Drugs Portfolio

4.6.2 Eli Lilly & Co. Antibiotics Drug Sales Forecast 2018-2028

4.6.2.1 Vancocin

4.6.2.2 Vancocin: Sales Forecast 2018-2028

4.6.2.3 Ceclor

4.6.2.4 Ceclor: Sales Forecast 2018-2028

4.6.3. Eli Lilly & Co.: SWOT Analysis

4.7 Melinta Therapeutics, Inc.: Overview

4.7.1 Melinta Therapeutics, Inc.: Antibiotics Drugs Portfolio

4.7.2 Melinta Therapeutics, Inc. Antibiotics Drug Sales Forecast 2018-2028

4.7.2.1 Orbactiv

4.7.2.2 Orbactiv: Sales Forecast 2018-2028

4.7.2.3 Others

4.7.2.4 Others: Sales Forecast 2018-2028

4.7.3. Melinta Therapeutics, Inc: SWOT Analysis

5. Leading Europe Antibiotics Drugs Manufacturers 2018-2028

5.1 Novartis: Overview

5.1.1 Novartis: Antibiotics Drugs Portfolio

5.1.2 Novartis Antibiotics Drug Sales Forecast 2018-2028

5.1.2.1 Vigamox

5.1.2.2 Vigamox: Sales Forecast 2018-2028

5.1.2.3 Ciprodex

5.1.2.4 Ciprodex: Sales Forecast 2018-2028

5.1.2.5 TOBI Podhaler

5.1.2.6 TOBI Podhaler: Sales Forecast 2018-2028

5.1.2.7 Cubicin

5.1.2.8 Cubicin: Sales Forecast 2018-2028

5.1.3 Novartis: SWOT Analysis

5.2 GlaxoSmithKline plc: Overview

5.2.1 GlaxoSmithKline plc: Antibiotics Drugs Portfolio

5.2.2 GlaxoSmithKline plc Antibiotics Drug Sales Forecast 2018-2028

5.2.2.1 Ceftin/Zinnat

5.2.2.2 Ceftin/Zinnat: Sales Forecast 2018-2028

5.2.2.3 Augmentin IR

5.2.2.4 Augmentin IR: Sales Forecast 2018-2028

5.2.2.5 Amoxil (Amoxicillin)

5.2.2.6 Amoxil: Sales Forecast 2018-2028

5.2.2.7 Others

5.2.2.8 Others: Sales Forecast 2018-2028

5.2.3 GlaxoSmithKline plc: SWOT Analysis

5.3 Bayer AG: Overview

5.3.1 Bayer AG: Antibiotics Drugs Portfolio

5.3.2 Bayer AG Antibiotics Drug Sales Forecast 2018-2028

5.3.2.1 Avelox

5.3.2.2 Avelox: Sales Forecast 2018-2028

5.3.2.3 Cipro/Cirpobay

5.3.2.4 Cipro/Cirpobay: Sales Forecast 2018-2028

5.3.3 Bayer AG: SWOT Analysis

5.4 Allergan plc: Overview

5.4.1 Allergan plc: Antibiotics Drugs Portfolio

5.4.2 Allergan plc Antibiotics Drug Sales Forecast 2018-2028

5.4.2.1 Zinforo/Teflaro

5.4.2.2 Zinforo/Teflaro: Sales Forecast 2018-2028

5.4.2.3 Dalbavancin

5.4.2.4 Dalbavancin: Sales Forecast 2018-2028

5.4.2.5 Others

5.4.2.6 Others: Sales Forecast 2018-2028

5.4.3. Allergan plc: SWOT Analysis

5.5. F. Hoffmann-La Roche AG: Overview

5.5.1 F. Hoffmann-La Roche AG: Antibiotics Drugs Portfolio

5.5.2. F. Hoffmann-La Roche AG Antibiotics Drug Sales Forecast 2018-2028

5.5.2.1 Rocephin

5.5.2.2 Rocephin: Sales Forecast 2018-2028

5.5.3. F. Hoffmann-La Roche AG: SWOT Analysis

5.6 Sanofi: Overview

5.6.1. Sanofi: Antibiotics Drugs Portfolio

5.6.2 Sanofi Antibiotics Drug Sales Forecast 2018-2028

5.6.2.1 Targocid

5.6.2.2 Targocid: Sales Forecast 2018-2028

5.6.2.3 Others

5.6.2.4 Others: Sales Forecast 2018-2028

5.6.3 Sanofi: SWOT Analysis

5.7 STADA Arzneimittel: Overview

5.7.1. STADA Arzneimittel: Antibiotics Drugs Portfolio

5.7.2 STADA Arzneimittel Antibiotics Drug Sales Forecast 2018-2028

5.7.2.1 Amoxicillin

5.7.2.2 Amoxicillin: Sales Forecast 2018-2028

5.7.2.3 Diclofenac Sodium

5.7.2.4 Diclofenac Sodium: Sales Forecast 2018-2028

5.7.3 STADA Arzneimittel: SWOT Analysis

6. Leading Japan Antibiotics Drugs Manufacturers 2018-2028

6.1 Shionogi & Co., Ltd.: Overview

6.2.1 Shionogi & Co., Ltd.: Antibiotics Drugs Portfolio

6.1.2 Shionogi & Co., Ltd. Antibiotics Drug Sales Forecast 2018-2028

6.1.2.1 Flomox/Flumarin

6.1.2.2 Flomox/Flumarin: Sales Forecast 2018-2028

6.1.2.3 Others

6.1.2.4 Others: Sales Forecast 2018-2028

6.1.3 Shionogi & Co., Ltd.: SWOT Analysis

6.2 Taisho Pharmaceutical Holdings: Overview

6.2.1 Taisho Pharmaceutical Holdings: Antibiotics Drugs Portfolio

6.2.2 Taisho Pharmaceutical Holdings Antibiotics Drug Sales Forecast 2018-2028

6.2.2.1 Geninax

6.2.2.2 Geninax: Sales Forecast 2018-2028

6.2.2.3 Biaxin/Clarith

6.2.2.4 Biaxin/Clarith: Sales Forecast 2018-2028

6.2.2.5 Zosyn/Tazocin

6.2.2.6 Zosyn/Tazocin: Sales Forecast 2018-2028

6.2.2.7 Other

6.2.2.8 Other: Sales Forecast 2018-2028

6.2.3. Taisho Pharmaceutical Holdings: SWOT Analysis

6.3 Daiichi Sankyo: Overview

6.3.1 Daiichi Sankyo: Antibiotics Drugs Portfolio

6.3.2 Daiichi Sankyo Antibiotics Drug Sales Forecast 2018-2028

6.3.2.1 Cravit

6.3.2.2 Cravit: Sales Forecast 2018-2028

6.3.2.3 Levaquin

6.3.2.4 Levaquin: Sales Forecast 2018-2028

6.3.2.5 Others

6.3.2.6 Others: Sales Forecast 2018-2028

6.3.3. Taisho Pharmaceutical Holdings: SWOT Analysis

6.4 Meiji Holdings Company, Ltd.: Overview

6.4.1. Meiji Holdings Company, Ltd.: Antibiotics Drugs Portfolio

6.4.2 Meiji Holdings Company, Ltd. Antibiotics Drug Sales Forecast 2018-2028

6.4.2.1 Meiact/Spectracef

6.4.2.2 Meiact/Spectracef: Sales Forecast 2018-2028

6.4.2.3 Others

6.4.2.4 Others: Sales Forecast 2018-2028

6.4.3. Meiji Holdings Company, Ltd

6.5 Astellas Pharma: Overview

6.5.1 Astellas Pharma: Antibiotics Drugs Portfolio

6.5.2 Astellas Pharma Antibiotics Drug Sales Forecast 2018-2028

6.5.2.1 Dificid

6.5.2.2 Dificid: Sales Forecast 2018-2028

6.5.2.3 Others

6.5.2.4 Others: Sales Forecast 2018-2028

6.5.3. Astellas Pharma

7. Leading Others Antibiotics Drugs Manufacturers 2018-2028

7.1 Sun Pharmaceutical Industries: Overview

7.1.1 Sun Pharmaceutical Industries: Antibiotics Drugs Portfolio

7.1.2 Sun Pharmaceutical Industries Antibiotics Drug Sales Forecast 2018-2028

7.1.2.1 Ciprofloxacin Hydrochloride

7.1.2.2 Ciprofloxacin Hydrochloride: Sales Forecast 2018-2028

7.1.2.3 Others

7.1.2.4 Others: Sales Forecast 2018-2028

7.1.3 Sun Pharmaceutical Industries: SWOT Analysis

7.2 Cipla: Overview

7.2.1 Cipla: Antibiotics Drugs Portfolio

7.2.2 Cipla Antibiotics Drug Sales Forecast 2018-2028

7.2.2.1 Amoxicillin

7.2.2.2 Amoxicillin: Sales Forecast 2018-2028

7.2.2.3 Others

7.2.2.4 Others: Sales Forecast 2018-2028

7.2.3. Cipla

7.3 Lupin Limited: Overview

7.3.1 Lupin: Antibiotics Drugs Portfolio

7.3.2 Lupin Antibiotics Drug Sales Forecast 2018-2028

7.3.2.1 Cefixime

7.3.2.2 Cefixime: Sales Forecast 2018-2028

7.3.2.3 Cephalexin

7.3.2.4 Cephalexin: Sales Forecast 2018-2028

7.3.2.5 Others

7.3.2.6 Others: Sales Forecast 2018-2028

7.3.3. Lupin: SWOT Analysis

7.4 Shanghai Pharmaceuticals Holding: Overview

7.4.1. Shanghai Pharmaceuticals Holding: Antibiotics Drugs Portfolio

7.4.2 Shanghai Pharmaceuticals Holding Antibiotics Drug Sales Forecast 2018-2028

7.4.2.1 Cefotaxime Sodium

7.4.2.2 Cefotaxime Sodium: Sales Forecast 2018-2028

7.4.2.3 Cefotiam Hydrochloride

7.4.2.4 Cefotiam Hydrochloride: Sales Forecast 2018-2028

7.4.2.5 Ceftriaxone Sodium

7.4.2.6 Ceftriaxone Sodium: Sales Forecast 2018-2028

7.4.3. Shanghai Pharmaceuticals Holding: SWOT Analysis

7.5 Dr. Reddy’s Laboratories: Overview

7.5.1 Dr. Reddy’s Laboratories: Antibiotics Drugs Portfolio

7.5.2.1 Amoxil

7.5.2.2 Amoxil: Sales Forecast 2018-2028

7.5.2.3 Ciprofloxacin Hydrochloride

7.5.2.4 Ciprofloxacin Hydrochloride: Sales Forecast 2018-2028

7.5.3. Dr. Reddy’s Laboratories: SWOT Analysis

7.6 TaiGen Biotechnology: Overview

7.6.1. TaiGen Biotechnology: Antibiotics Drugs Portfolio

7.6.2 TaiGen Biotechnology Antibiotics Drug Sales Forecast 2018-2028

7.6.2.1 Taigexyn

7.6.2.2 Taigexyn: Sales Forecast 2018-2028

7.4.3. TaiGen Biotechnology


8. Conclusions

8.1 The World Antibiotics Drugs Market in 2016 and 2017

8.1.1 Current Leading Antibiotics Drugs Segments

8.1.2 Leading Antibiotics Drugs Manufacturer Markets

8.2 World Antibiotics drugs Market Forecast 2018-2028

8.3 The Future of the Antibiotics drugs Market?




Appendix

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form


List of Tables

Table 3.1 Global Antibiotics Drugs Market by Product Type: Revenue ($m) and Market Share (%), 2017

Table 3.2 Global Antibiotics Drugs Market Forecast, By Automation Type: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 3.3 Top 10 Antibiotics Drugs Manufacturer: Revenue ($m), Market Share (%), 2017

Table 3.4 Top 25 Antibiotics Drugs Manufacturer Revenue ($m), 2017

Table 3.5 Global Antibiotics Drugs Market Forecast, By Manufacturer: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 3.6 Global Antibiotics Drugs Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 3.7 Cephalosporins Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 3.8 Penicillins Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 3.9 Fluoroquinolones Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 3.10 Macrolides Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 3.11 Carbapenems Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 3.12 Others Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028

Table 4.1 Pfizer, Inc.: Overview, 2018

Table 4.2 Pfizer: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 4.3 Pfizer Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.4 Pfizer: Sulperazon Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.5 Pfizer: Unasyn Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.6 Pfizer: Zithromax Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.7 Pfizer: Dalacin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.8 Pfizer: Merrem/Meropen Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.9 Pfizer: Zyvox Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.10 Pfizer: Tygacil Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.11 Pfizer: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.12 Pfizer: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 4.13 Merck & Co.: Overview, 2018

Table 4.14 Merck & Co.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 4.15 Merck & Co. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.16 Merck & Co.: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.17 Merck & Co.: Invanz Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.18 Merck & Co.: Avelox Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.19 Merck & Co.: Primaxin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.20 Merck & Co.: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.21 Merck & Co.: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 4.22 Johnson & Johnson: Overview, 2018

Table 4.23 Johnson & Johnson: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 4.24 Johnson & Johnson Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.25 Johnson & Johnson: Zeftera Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.26 Johnson & Johnson: Sirturo Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.27 Johnson & Johnson: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.28 Johnson & Johnson: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 4.29 Cubist Pharmaceuticals: Overview, 2018

Table 4.30 Cubist Pharmaceuticals: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 4.31 Cubist Pharmaceuticals Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.32 Cubist Pharmaceuticals: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.33 Cubist Pharmaceuticals: Sivextro Oral Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.34 Cubist Pharmaceuticals: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.35 Cubist Pharmaceuticals: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 4.36 Abbott Laboratories: Overview, 2018

Table 4.37 Abbott Laboratories: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 4.38 Abbott Laboratories Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.39 Abbott Laboratories: Baxin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.40 Abbott Laboratories: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.41 Abbott Laboratories: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 4.42 Eli Lilly & Co.: Overview, 2018

Table 4.43 Eli Lilly & Co.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 4.44 Eli Lilly & Co. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.45 Eli Lilly & Co.: Vancocin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.46 Eli Lilly & Co.: Ceclor Revenue ($m), AGR (%) and CAGR (%), 2016-2021

Table 4.47 Eli Lilly & Co.: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 4.48 Melinta Therapeutics, Inc.: Overview, 2018

Table 4.49 Melinta Therapeutics, Inc.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 4.50 Melinta Therapeutics, Inc. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.51 Melinta Therapeutics, Inc: Orbactiv Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.52 Melinta Therapeutics, Inc: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 4.53 Melinta Therapeutics, Inc.: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 5.1 Novartis: Overview, 2018

Table 5.2 Novartis: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 5.3 Novartis Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.4 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.5 Novartis: Ciprodex Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.6 Novartis: TOBI Podhaler Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.7 Novartis: Cubicin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.8 Novartis: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 5.9 GlaxoSmithKline plc: Overview, 2018

Table 5.10 GlaxoSmithKline plc: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 5.11 GlaxoSmithKline plc Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.12 GlaxoSmithKline plc: Ceftin/Zinnat Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.13 GlaxoSmithKline plc: Augmentin IR Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.14 GlaxoSmithKline plc: Amoxil Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.15 GlaxoSmithKline plc: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.16 GlaxoSmithKline plc: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 5.17 Bayer AG: Overview, 2018

Table 5.18 Bayer AG: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 5.19 Bayer AG Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.20 Bayer AG: Avelox Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.21 Bayer AG: Cipro/Cirpobay Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.22 Bayer AG: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 5.23 Allergan plc: Overview, 2018

Table 5.24 Allergan plc: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 5.25 Allergan plc Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.26 Allergan plc: Zinforo/Teflaro Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.27 Allergan plc: Dalbavancin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.28 Allergan plc: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.29 Allergan plc: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 5.30 F. Hoffmann-La Roche AG: Overview, 2018

Table 5.31 F. Hoffmann-La Roche AG: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 5.32 F. Hoffmann-La Roche AG Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.33 F. Hoffmann-La Roche AG: Rocephin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.34 F. Hoffmann-La Roche AG: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 5.35 Sanofi: Overview, 2018

Table 5.36 Sanofi: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 5.37 Sanofi Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.38 Sanofi: Targocid Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.39 Sanofi: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.40 Sanofi: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 5.41 STADA Arzneimittel: Overview, 2018

Table 5.42 STADA Arzneimittel: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 5.43 STADA Arzneimittel Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.44 STADA Arzneimittel: Amoxicillin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.45 STADA Arzneimittel: Diclofenac Sodium Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 5.46 STADA Arzneimittel: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 6.1 Shionogi & Co., Ltd.: Overview, 2018

Table 6.2 Shionogi & Co., Ltd.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 6.3 Shionogi & Co., Ltd. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.4 Shionogi & Co., Ltd.: Flomox/Flumarin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.5 Shionogi & Co., Ltd.: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.6 Shionogi & Co., Ltd.: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 6.7 Taisho Pharmaceutical Holdings: Overview, 2018

Table 6.8 Taisho Pharmaceutical Holdings: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 6.9 Taisho Pharmaceutical Holdings Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.10 Taisho Pharmaceutical Holdings: Geninax Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.11 Taisho Pharmaceutical Holdings: Biaxin/Clarith Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.12 Taisho Pharmaceutical Holdings: Zosyn/Tazocin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.13 Taisho Pharmaceutical Holdings: Other Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.14 Taisho Pharmaceutical Holdings: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 6.15 Daiichi Sankyo: Overview, 2018

Table 6.16 Daiichi Sankyo: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 6.17 Daiichi Sankyo Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.18 Daiichi Sankyo: Cravit Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.19 Daiichi Sankyo: Levaquin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.20 Daiichi Sankyo: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.21 Taisho Pharmaceutical Holdings: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 6.22 Meiji Holdings Company, Ltd.: Overview, 2018

Table 6.23 Meiji Holdings Company, Ltd.: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 6.24 Meiji Holdings Company, Ltd. Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.25 Meiji Holdings Company, Ltd.: Meiact/Spectracef Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.26 Meiji Holdings Company, Ltd.: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.27 Meiji Holdings Company, Ltd: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 6.28 Astellas Pharma: Overview, 2018

Table 6.29 Astellas Pharma: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 6.30 Astellas Pharma Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.31 Astellas Pharma: Dificid Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.32 Astellas Pharma: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 6.33 Astellas Pharma: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 7.1 Sun Pharmaceutical Industries: Overview, 2018

Table 7.2 Sun Pharmaceutical Industries: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 7.3 Sun Pharmaceutical Industries Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.4 Sun Pharmaceutical Industries: Ciprofloxacin Hydrochloride Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.5 Sun Pharmaceutical Industries: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.6 Sun Pharmaceutical Industries: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 7.7 Cipla: Overview, 2018

Table 7.8 Cipla: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 7.9 Cipla Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.10 Cipla: Amoxicillin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.11 Cipla: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.12 Cipla: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 7.13 Lupin: Overview, 2018

Table 7.14 Lupin: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 7.15 Lupin Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.16 Lupin: Cefixime Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.17 Lupin: Cephalexin Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.18 Lupin: Others Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.19 Lupin: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 7.20 Shanghai Pharmaceuticals Holding: Overview, 2018

Table 7.21 Shanghai Pharmaceuticals Holding: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 7.22 Shanghai Pharmaceuticals Holding Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.23 Shanghai Pharmaceuticals Holding: Cefotaxime Sodium Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.24 Shanghai Pharmaceuticals Holding: Cefotiam Hydrochloride Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.25 Shanghai Pharmaceuticals Holding: Ceftriaxone Sodium Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.26 Shanghai Pharmaceuticals Holding: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 7.27 Dr. Reddy’s Laboratories: Overview, 2018

Table 7.28 Dr. Reddy’s Laboratories: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 7.29 Dr. Reddy’s Laboratories Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.30 Dr. Reddy’s Laboratories: Amoxil Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.31 Dr. Reddy’s Laboratories: Ciprofloxacin Hydrochloride Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.32 Dr. Reddy’s Laboratories: Antibiotics Drugs Market SWOT Analysis, 2018-2028

Table 7.33 TaiGen Biotechnology: Overview, 2018

Table 7.34 TaiGen Biotechnology: Antibiotics Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017

Table 7.35 TaiGen Biotechnology Antibiotics Drug Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.36 TaiGen Biotechnology: Taigexyn Revenue ($m), AGR (%) and CAGR (%), 2016-2028

Table 7.37 TaiGen Biotechnology: Antibiotics Drugs Market SWOT Analysis, 2018-2028


List of Figure

Figure 1.1 Global Antibiotics Drugs Manufacturer Market Segmentation Overview

Figure 3.1 Global Antibiotics Drugs Market by Product Type: Market Share (%), 2017

Figure 3.2 Global Antibiotics Drugs Market by Product Type: Market Share (%), 2017

Figure 3.3 Global Antibiotics Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028

Figure 3.4 Top 10 Antibiotics Drugs Manufacturer: Revenue ($m), 2017

Figure 3.5 Top 10 Antibiotics Drugs Manufacturer: Market Share (%), 2017

Figure 3.6 Global Antibiotics Drugs Market by Automation Type: Market Share (%), 2017

Figure 3.7 Global Antibiotics Drugs Market by Automation Type: Market Share (%), 2022

Figure 3.8 Global Antibiotics Drugs Market by Automation Type: Market Share (%), 2028

Figure 3.9 Global Cephalosporins Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028

Figure 3.10 Global Penicillins Market Forecast: Revenue ($m), AGR (%), 2016-2028

Figure 3.11 Global Fluoroquinolones Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028

Figure 3.12 Global Macrolides Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028

Figure 3.13 Global Carbapenems Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028

Figure 3.14 Global Others Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2028

Figure 4.1 Pfizer Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 4.2 Pfizer: Sulperazon: Revenue ($m), AGR (%), 2016-2028

Figure 4.3 Pfizer: Unasyn Revenue ($m), AGR (%), 2016-2028

Figure 4.4 Pfizer: Zithromax Revenue ($m), AGR (%), 2016-2028

Figure 4.5 Pfizer: Dalacin Revenue ($m), AGR (%), 2016-2028

Figure 4.6 Pfizer: Merrem/Meropen Revenue ($m), AGR (%), 2016-2028

Figure 4.7 Pfizer: Zyvox Revenue ($m), AGR (%), 2016-2028

Figure 4.8 Pfizer: Tygacil Revenue ($m), AGR (%), 2016-2028

Figure 4.9 Others: Tygacil Revenue ($m), AGR (%), 2016-2028

Figure 4.10 Merck & Co. Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 4.11 Merck & Co.: Cubicin: Revenue ($m), AGR (%), 2016-2028

Figure 4.12 Merck & Co.: Invanz Revenue ($m), AGR (%), 2016-2028

Figure 4.13 Merck & Co.: Avelox Revenue ($m), AGR (%), 2016-2028

Figure4.14 Merck & Co.: Primaxin Revenue ($m), AGR (%), 2016-2028

Figure 4.15 Merck & Co.: Others Revenue ($m), AGR (%), 2016-2028

Figure 4.16 Johnson & Johnson Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 4.17 Johnson & Johnson: Zeftera: Revenue ($m), AGR (%), 2016-2028

Figure 4.18 Johnson & Johnson: Sirturo Revenue ($m), AGR (%), 2016-2028

Figure 4.19 Johnson & Johnson: Others Revenue ($m), AGR (%), 2016-2028

Figure 4.20 Cubist Pharmaceuticals Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 4.21 Cubist Pharmaceuticals: Cubicin: Revenue ($m), AGR (%), 2016-2028

Figure 4.22 Cubist Pharmaceuticals: Sivextro Oral Revenue ($m), AGR (%), 2016-2028

Figure 4.23 Cubist Pharmaceuticals: Others Revenue ($m), AGR (%), 2016-2028

Figure 4.24 Abbott Laboratories Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 4.25 Abbott Laboratories: Baxin Revenue ($m), AGR (%), 2016-2028

Figure 4.26 Abbott Laboratories: Tedizolid Revenue ($m), AGR (%), 2016-2028

Figure 4.27 Eli Lilly & Co. Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 4.28 Eli Lilly & Co.: Vancocin Revenue ($m), AGR (%), 2016-2028

Figure 4.29 Eli Lilly & Co.: Ceclor Revenue ($m), AGR (%), 2016-2021

Figure 4.30 Melinta Therapeutics, Inc.Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 4.31 Melinta Therapeutics, Inc.: Orbactiv Revenue ($m), AGR (%), 2016-2028

Figure 4.32 Melinta Therapeutics, Inc.: Others Revenue ($m), AGR (%), 2016-2028

Figure 5.1 Novartis Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 5.2 Novartis: Vigamox Revenue ($m), AGR (%), 2016-2028

Figure 5.3 Novartis: Ciprodex Revenue ($m), AGR (%), 2016-2028

Figure 5.4 Novartis: TOBI Podhaler Revenue ($m), AGR (%), 2016-2028

Figure 5.5 Novartis: Cubicin Revenue ($m), AGR (%), 2016-2028

Figure 5.6 GlaxoSmithKline plc Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 5.7 GlaxoSmithKline plc: Ceftin/Zinnat: Revenue ($m), AGR (%), 2016-2028

Figure 5.8 GlaxoSmithKline plc: Augmentin IR Revenue ($m), AGR (%), 2016-2028

Figure 5.9 GlaxoSmithKline plc: Amoxil Revenue ($m), AGR (%), 2016-2028

Figure 5.10 GlaxoSmithKline plc: Others Revenue ($m), AGR (%), 2016-2028

Figure 5.11 Bayer AG Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 5.12 Bayer AG: Avelox Revenue ($m), AGR (%), 2016-2028

Figure 5.13 Bayer AG: Cipro/Cirpobay Revenue ($m), AGR (%), 2016-2028

Figure 5.14 Allergan plc Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 5.15 Allergan plc: Zinforo/Teflaro Revenue ($m), AGR (%), 2016-2028

Figure 5.16 Allergan plc: Dalbavancin Revenue ($m), AGR (%), 2016-2028

Figure 5.17 Allergan plc: Others Revenue ($m), AGR (%), 2016-2028

Figure 5.18 F. Hoffmann-La Roche AG Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 5.19 F. Hoffmann-La Roche AG: Rocephin Revenue ($m), AGR (%), 2016-2028

Figure 5.20 Sanofi Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 5.21 Sanofi: Targocid Revenue ($m), AGR (%), 2016-2028

Figure 5.22 Sanofi: Others Revenue ($m), AGR (%), 2016-2028

Figure 5.23 STADA ArzneimittelAntibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 5.24 STADA Arzneimittel: Amoxicillin Revenue ($m), AGR (%), 2016-2028

Figure 5.25 STADA Arzneimittel: Diclofenac Sodium Revenue ($m), AGR (%), 2016-2028

Figure 6.1 Shionogi & Co., Ltd. Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 6.2 Shionogi & Co., Ltd.: Flomox/Flumarin Revenue ($m), AGR (%), 2016-2028

Figure 6.3 Shionogi & Co., Ltd.: Others Revenue ($m), AGR (%), 2016-2028

Figure 6.4 Taisho Pharmaceutical Holdings Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 6.5 Taisho Pharmaceutical Holdings: Geninax Revenue ($m), AGR (%), 2016-2028

Figure 6.6 Taisho Pharmaceutical Holdings: Biaxin/Clarith Revenue ($m), AGR (%), 2016-2028

Figure 6.7 Taisho Pharmaceutical Holdings: Zosyn/Tazocin Revenue ($m), AGR (%), 2016-2028

Figure 6.8 Taisho Pharmaceutical Holdings: Other Revenue ($m), AGR (%), 2016-2028

Figure 6.9 Daiichi Sankyo Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 6.10 Daiichi Sankyo: Cravit Revenue ($m), AGR (%), 2016-2028

Figure 6.11 Daiichi Sankyo: Levaquin Revenue ($m), AGR (%), 2016-2028

Figure 6.12 Daiichi Sankyo: Others Revenue ($m), AGR (%), 2016-2028

Figure 6.13 Meiji Holdings Company, Ltd. Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 6.14 Meiji Holdings Company, Ltd.: Meiact/Spectracef Revenue ($m), AGR (%), 2016-2028

Figure 6.15 Meiji Holdings Company, Ltd.: Others Revenue ($m), AGR (%), 2016-2028

Figure 6.16 Astellas Pharma Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 6.17 Astellas Pharma: Dificid Revenue ($m), AGR (%), 2016-2028

Figure 6.18 Astellas Pharma: Tedizolid Revenue ($m), AGR (%), 2016-2028

Figure 7.1 Sun Pharmaceutical Industries Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 7.2 Sun Pharmaceutical Industries: Ciprofloxacin Hydrochloride Revenue ($m), AGR (%), 2016-2028

Figure 7.3 Sun Pharmaceutical Industries: Others Revenue ($m), AGR (%), 2016-2028

Figure 7.4 Cipla Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 7.5 Cipla: Amoxicillin Revenue ($m), AGR (%), 2016-2028

Figure 7.6 Cipla: Others Revenue ($m), AGR (%), 2016-2028

Figure 7.7 Lupin Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 7.8 Lupin: Cefixime Revenue ($m), AGR (%), 2016-2028

Figure 7.9 Lupin: Cephalexin Revenue ($m), AGR (%), 2016-2028

Figure 7.10 Lupin: Others Revenue ($m), AGR (%), 2016-2028

Figure 7.11 Shanghai Pharmaceuticals Holding Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 7.12 Shanghai Pharmaceuticals Holding: Cefotaxime Sodium Revenue ($m), AGR (%), 2016-2028

Figure 7.13 Shanghai Pharmaceuticals Holding: Tedizolid Revenue ($m), AGR (%), 2016-2028

Figure 7.14 Shanghai Pharmaceuticals Holding: Ceftriaxone Sodium Revenue ($m), AGR (%), 2016-2028

Figure 7.15 Dr. Reddy’s Laboratories Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 7.16 Dr. Reddy’s Laboratories: Amoxil Revenue ($m), AGR (%), 2016-2028

Figure 7.17 Dr. Reddy’s Laboratories: Ciprofloxacin Hydrochloride Revenue ($m), AGR (%), 2016-2028

Figure 7.18 TaiGen Biotechnology Antibiotics Drug: Revenue ($m), AGR (%), 2016-2028

Figure 7.19 TaiGen Biotechnology: Taigexyn Revenue ($m), AGR (%), 2016-2028

Figure 8.1 Global Antibiotics drugs Market by Product Type: Market Share (%), 2016

Figure 8.2 Top Antibiotics drugs Manufacturer Share (%), 2016

★調査レポート[世界の抗生物質メーカー上位25社] ( Top 25 Antibiotic Drugs Manufacturers 2018 / VGN808069) 販売に関する免責事項
[世界の抗生物質メーカー上位25社] ( Top 25 Antibiotic Drugs Manufacturers 2018 / VGN808069) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆